JP2015509075A - ノルイボガインの硫酸エステル - Google Patents

ノルイボガインの硫酸エステル Download PDF

Info

Publication number
JP2015509075A
JP2015509075A JP2014545968A JP2014545968A JP2015509075A JP 2015509075 A JP2015509075 A JP 2015509075A JP 2014545968 A JP2014545968 A JP 2014545968A JP 2014545968 A JP2014545968 A JP 2014545968A JP 2015509075 A JP2015509075 A JP 2015509075A
Authority
JP
Japan
Prior art keywords
compound
pain
patient
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509075A5 (enExample
Inventor
リチャード ディー． グレス，
リチャード ディー． グレス，
ロバート エム． モリアーティ，
ロバート エム． モリアーティ，
Original Assignee
デメレックス， インコーポレイテッド
デメレックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デメレックス， インコーポレイテッド, デメレックス， インコーポレイテッド filed Critical デメレックス， インコーポレイテッド
Publication of JP2015509075A publication Critical patent/JP2015509075A/ja
Publication of JP2015509075A5 publication Critical patent/JP2015509075A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014545968A 2011-12-09 2012-12-03 ノルイボガインの硫酸エステル Pending JP2015509075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569144P 2011-12-09 2011-12-09
US61/569,144 2011-12-09
PCT/US2012/067627 WO2013085849A2 (en) 2011-12-09 2012-12-03 Sulfate esters of noribogaine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017161033A Division JP2017203046A (ja) 2011-12-09 2017-08-24 ノルイボガインの硫酸エステル

Publications (2)

Publication Number Publication Date
JP2015509075A true JP2015509075A (ja) 2015-03-26
JP2015509075A5 JP2015509075A5 (enExample) 2016-01-21

Family

ID=48575046

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014545968A Pending JP2015509075A (ja) 2011-12-09 2012-12-03 ノルイボガインの硫酸エステル
JP2017161033A Pending JP2017203046A (ja) 2011-12-09 2017-08-24 ノルイボガインの硫酸エステル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017161033A Pending JP2017203046A (ja) 2011-12-09 2017-08-24 ノルイボガインの硫酸エステル

Country Status (5)

Country Link
US (1) US8853201B2 (enExample)
EP (1) EP2788356A4 (enExample)
JP (2) JP2015509075A (enExample)
CA (1) CA2855990A1 (enExample)
WO (1) WO2013085849A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045481B2 (en) * 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2014143201A1 (en) * 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
ES2955490T3 (es) 2014-11-26 2023-12-01 Demerx Inc Métodos y composiciones para potenciar la acción de los analgésicos opioides mediante el uso de alcaloides de la iboga
WO2016134019A1 (en) * 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195384A (ja) * 1986-02-24 1987-08-28 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
WO1999011250A2 (en) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
WO2010036998A2 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) * 1957-11-19 Derivatives of the ibogaine alkaloids
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
DE69635737D1 (de) * 1995-08-08 2006-04-06 Albany Medical College Albany Ibogamin verwandte verbindungen
US5616575A (en) * 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195384A (ja) * 1986-02-24 1987-08-28 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
WO1999011250A2 (en) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
WO2010036998A2 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAZAR, S. ET AL.: "Synthesis and biological activity of the phosphate and sulfate esters of naloxone and naltrexone", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 29(1), JPN6016030716, 1994, pages 45 - 53, ISSN: 0003377937 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine

Also Published As

Publication number Publication date
US8853201B2 (en) 2014-10-07
WO2013085849A3 (en) 2014-12-18
WO2013085849A2 (en) 2013-06-13
US20130165425A1 (en) 2013-06-27
CA2855990A1 (en) 2013-06-13
JP2017203046A (ja) 2017-11-16
EP2788356A4 (en) 2015-10-21
EP2788356A2 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
JP2017203047A (ja) ノルイボガインのリン酸エステル
JP2017203046A (ja) ノルイボガインの硫酸エステル
US9586954B2 (en) N-substituted noribogaine prodrugs
US8476314B2 (en) Substance with sedative effect
CA2781436C (en) Arachidonic acid analogs and methods for analgesic treatment using same
JP2003503450A5 (enExample)
TW200418475A (en) Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists
CN101360501A (zh) 物质滥用的治疗
ES2269467T3 (es) Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
BR112019022902A2 (pt) composição, composição farmacêutica, uso da composição terapeuticamente eficaz, método e uso de uma composição terapeuticamente eficaz em um método de tratamento
CA3198547A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
JP2023133571A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
CN101272776B (zh) 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CN104744480A (zh) 7-氮鎓双环[2.2.1]庚烷衍生物、其制备方法、及其制可药用途
MXPA00012248A (es) Incrementadores de acetilcolina.
JP6448990B2 (ja) 薬物依存症の治療薬としてのＴｒｋＢ受容体拮抗薬
JP2025160326A (ja) 処置方法
Putney Biochemical interactions and pharmacodynamic effects of intravenous anesthetic agents in cannabis users.
CN121129852A (zh) 包含右美沙芬的药物组合物及其用途
CN107382987A (zh) 一种具有预防和治疗创伤性脑损伤活性的化合物及其制备方法和用途
MX2008012212A (es) Metodos para tratar trastornos cognitivos y otros afines.
Ajit et al. Illicit Drugs and their Assessment: A Brief Review
EA041547B1 (ru) Модуляторы рецептора гамма-аминомасляной кислоты типа a против расстройств настроения
WO2008038160A2 (en) A substance with sedative effect for use in the treatment of neurotic disorders
TW200848020A (en) Use of 5-HT6 antagonists to prevent relapse into addiction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170824